stonks4u
Log inSign up free
OCUL logo

OCUL Ocular Therapeutix, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$10.74
+0.70 (+6.97%)

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage …

Market Cap: $2.35Bwww.ocutx.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Revenue

$13.47M+10.88%
$10.70M$12.83M$14.95M$17.08M
Sep 2021Jun 2026

Quote

Day Range
$10.51 – $11.20
52-Week Range
$6.23 – $16.44
Volume
$8.72M
Market Cap
$2.35B
50-Day Avg
$9.25
200-Day Avg
$9.98
Prev Close
$10.04
Open
$10.81

Valuation & Ratios

P/E Ratio
-8.55
EPS
$-1.42
P/B Ratio
3.47
P/S Ratio
43.86
Debt/Equity
0.12
Current Ratio
15.39
Dividend Yield
+0.0%
Gross Margin
+87.3%

Returns & Efficiency

Return on Equity
-40.6%
Return on Assets
-32.9%
FCF Yield
-9.5%
EV/EBITDA
-6.47

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$51.82M$-265.94M$-1.42
2024$63.72M$-193.51M$-1.22
2023$58.44M$-80.74M$-1.09
2022$51.49M$-71.04M$-1.04
2021$43.52M$-6.55M$-1.05

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-0.36 per share

3of 7 quarters beat consensus

Typical surprise -11.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 3$-0.35 vs $-0.40beat
  • Tue, May 5$-0.41 vs $-0.32miss
  • Thu, Feb 5$-0.29 vs $-0.33beat
  • Tue, Nov 4$-0.37 vs $-0.39beat
  • Tue, Aug 5$-0.39 vs $-0.35miss
  • Mon, May 5$-0.37 vs $-0.29miss

Estimates and results for OCUL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by OCUL officers and directors.

Bought
$461k

1 trade

Sold
$3.5m

29 trades

  • Waheed Nadiasold
    Chief Medical Officer·14,828 @ $8.27·$123k·Jun 3, 2026·filing
  • Dugel Pravinsold
    director, officer: See Remarks·21,156 @ $8.20·$173k·May 26, 2026·filing
  • Kaiser Petersold
    Chief Development Officer·2,967 @ $8.20·$24k·May 26, 2026·filing
  • Heier Jeffrey S.sold
    Chief Scientific Officer·3,018 @ $8.20·$25k·May 26, 2026·filing
  • Nayak Sanjaysold
    Chief Strategy Officer·1,858 @ $8.20·$15k·May 26, 2026·filing
  • Dugel Pravinsold
    director, officer: See Remarks·20,056 @ $8.28·$166k·Feb 23, 2026·filing
  • Kaiser Petersold
    Chief Development Officer·2,810 @ $8.28·$23k·Feb 23, 2026·filing
  • Heier Jeffrey S.sold
    Chief Scientific Officer·3,057 @ $8.28·$25k·Feb 23, 2026·filing

70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

OCULhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsbenzinga.com·5h ago·Neutral

    Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).

    View source ↗